TVTX
Travere Therapeutics Inc

1,070
Mkt Cap
$3.09B
Volume
4.25M
52W High
$35.86
52W Low
$12.91
PE Ratio
-31.84
TVTX Fundamentals
Price
$34.53
Prev Close
$35.16
Open
$34.58
50D MA
$24.84
Beta
1.36
Avg. Volume
1.94M
EPS (Annual)
-$4.08
P/B
41.99
Rev/Employee
$605,649.35
Loading...
Loading...
News
all
press releases
Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of +190.32% and +59.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Travere Therapeutics Reports Third Quarter 2025 Financial Results
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update. We delivered outstanding commercial performance in the third...
Business Wire·4d ago
News Placeholder
Travere Therapeutics to Report Third Quarter 2025 Financial Results
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company...
Business Wire·11d ago
News Placeholder
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney...
Business Wire·18d ago
News Placeholder
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Zacks·19d ago
News Placeholder
What Makes Travere (TVTX) a New Strong Buy Stock
Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·20d ago
News Placeholder
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Zacks·21d ago
News Placeholder
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of...
Business Wire·24d ago
News Placeholder
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
Zacks·2mo ago

Latest TVTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.